Furthermore, co‐treatment with venetoclax and the XPO1 inhibitor, selinexor, showed enhanced efficacy in myeloma cells under hypoxic conditions, indicating that this combination therapy may be a promising approach for targeting myeloma cells in the hypoxic BM niche. This evidence concerns the gene XPO1 and plasma cell myeloma.